Dr Chris Wynne co-authored the manuscript for INVICTAN-1 – A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects. It has been e-published by the Journal of Expert Opinion on Investigational Drugs.

http://www.tandfonline.com/doi/full/10.1080/13543784.2017.1347635